Eight-Gene Blood Test Shows Striking Accuracy in Detecting Heart Attacks

Acute myocardial infarction, the medical term for a heart attack, kills roughly nine million people every year and remains the single deadliest manifestation of coronary artery disease. Even as revascularization, antithrombotic drugs, and cardiac rehabilitation have dramatically improved short-term survival, a troubling share of survivors go on to develop heart failure, dangerous arrhythmias, or new coronary events. A study published in Frontiers in Cardiovascular Medicine now offers a fresh angle on this persistent problem: an eight-gene diagnostic index, mined from public blood transcriptome data with rigorous machine learning, that distinguishes heart attack patients from controls with remarkable accuracy while simultaneously mapping the inflammatory storm that drives the disease.

The research team, led by Chengfeng Pan and colleagues at Cangnan Hospital of Wenzhou Medical University in China, took an unusually disciplined approach to a common pitfall in genomics. Rather than pooling datasets from different microarray platforms and hoping for the best, they analyzed four Gene Expression Omnibus datasets study by study, without any cross-platform batch harmonization. The discovery cohort, GSE59867, contained 111 admission samples from patients with ST-segment elevation myocardial infarction and 46 samples from patients with stable coronary artery disease. Three further cohorts, GSE48060, GSE60993, and GSE66360, totaling 348 participants across the study, served as fully independent validation sets. This design choice matters: by refusing to merge technically incompatible data, the researchers ensured that any signal surviving validation was biological rather than an artifact of preprocessing.

The first layer of analysis painted a vivid picture of the immune landscape in heart attack. Using marker-based scoring of nine immune cell programs, the team found that neutrophil and classical monocyte signatures were markedly elevated in STEMI patients, with Cliff’s delta effect sizes of 0.635 and 0.611 respectively and false discovery rates below 10^-8. In mirror image, natural killer cell and CD8 T-cell programs were suppressed. This myeloid surge with lymphoid retreat is exactly what cardiologists would predict from the biology of ischemia-reperfusion: dying heart muscle releases danger-associated molecular patterns that trigger neutrophil infiltration, monocyte extravasation, and macrophage activation. When that inflammatory wave clears debris and scaffolds repair, it is beneficial; when it persists, it drives fibrosis, maladaptive remodeling, and progressive cardiac dysfunction.

To connect genes to this immune picture, the researchers applied weighted gene co-expression network analysis, or WGCNA, to the 1,000 most variable genes in the discovery cohort. The network resolved into eight modules, and the largest, containing 215 genes, showed the strongest association with STEMI status, with a point-biserial correlation of 0.591 and an FDR of 2.97 x 10^-15. Gene ontology testing revealed that inflammatory response was the dominant biological theme within this module, with 20 of its 215 genes belonging to that pathway at an FDR of 2.41 x 10^-10. Hub topology analysis confirmed that genes most connected within the module were also the ones most strongly tied to disease status, a pattern that lends biological coherence to the statistical signal.

The centerpiece of the study, however, is the machine learning pipeline that distilled this complexity into a compact diagnostic index. The team used nested cross-validation, a design that strictly separates feature selection from performance estimation to prevent information leakage and overfitting. Within each of 25 outer test folds, genes were ranked by Welch-test p-value and the top eight selected; four algorithms, including L2-regularized logistic regression, linear support vector machines, random forest, and gradient boosting, then produced predictions. Three genes, BAX, EDA2R, and MCEMP1, were selected in every single outer fold, a striking consistency. The final fixed model settled on eight genes: BAX, EDA2R, MCEMP1, SOCS3, ASGR2, RNASE1, ADM, and KPNA5.

The performance numbers are eye-catching. In the discovery cohort, the repeated out-of-fold area under the receiver operating characteristic curve, a standard measure of diagnostic discrimination, reached 0.984 for logistic regression and 0.986 for the linear SVM, with a Brier score of 0.080 indicating good calibration. More importantly, the index transported to independent data: validation AUCs were 0.863 in GSE48060, 0.876 in GSE66360, and 0.655 in GSE60993. The authors are candid about the weaker result. GSE60993 mixed STEMI and NSTEMI patients, used whole blood rather than the PBMC or enriched cell preparations of the other cohorts, and contained only 24 samples, all factors that plausibly diluted the myeloid inflammatory signal the index was built to detect. A fourth dataset, GSE62646, yielded an AUC of 0.995 but was treated only as a technical sensitivity analysis because participant overlap with the discovery cohort could not be excluded.

What do the eight genes actually do? The study weaves them into a mechanistic narrative of sterile cardiac inflammation. BAX is a pro-apoptotic regulator of cell death, fitting for a disease defined by cardiomyocyte necrosis. EDA2R, which carried the largest positive coefficient in the final model with an odds ratio of 2.72 per standardized unit, is increasingly linked to aging and degenerative signaling. MCEMP1 marks mast cells and myeloid populations, while SOCS3 is a feedback inhibitor of cytokine signaling that spikes during inflammatory activation. ASGR2, RNASE1, ADM, and KPNA5 round out the panel with roles spanning hepatic clearance, extracellular RNA degradation, hypoxia adaptation, and nuclear transport. Notably, six of the eight genes retained the same direction of disease association across all five cohorts examined, though BAX and EDA2R reversed direction in two, a reminder that cross-cohort heterogeneity is real even when overall performance holds.

Pathway analysis added further depth. Among discovery genes ranked by test statistic, the strongest positive Hallmark signal was epithelial-mesenchymal transition, but IL-6/JAK/STAT3 signaling, inflammatory response, hypoxia, reactive oxygen species response, and TNF-alpha/NF-kB signaling all ranked positively as well, forming a connected network of leading-edge genes. A single-cell dataset, GSE121893, provided cellular context showing that the model genes display distinct expression patterns across endothelial cells, smooth-muscle cells, fibroblasts, and macrophages, with MCEMP1 concentrated in macrophages. The authors are careful to note that this dataset contained no actual AMI specimens, so it offers context rather than proof of AMI-specific localization.

The team also ran laboratory experiments to ground the computational findings in wet-lab reality. Using ATCC-authenticated THP-1 monocytes differentiated into macrophage-like cells and stimulated with lipopolysaccharide and ATP to activate the NLRP3 inflammasome, plus EA.hy926 endothelial cells subjected to hypoxia-reoxygenation, they measured four prespecified inflammatory transcripts by RT-qPCR. All four rose significantly: CXCL10 increased 3.82-fold, IL6 4.15-fold, NLRP3 2.94-fold, and CASP1 3.47-fold, each across three independent biological replicates. Because these transcripts were chosen as inflammasome-axis markers rather than members of the eight-gene model itself, the experiment corroborates the inflammatory program underlying AMI rather than directly validating the diagnostic index, a distinction the authors draw explicitly.

The study is equally forthright about its limits. Two exploratory outcome analyses, predicting six-month heart failure progression in 17 patients and 18-month recurrent events in 31, produced AUCs of 0.819 and 0.569 respectively, results the authors label descriptive only, given tiny event counts and the absence of patient-level censoring data. No Kaplan-Meier curves or hazard ratios were computed, and an exploratory two-subtype clustering of STEMI patients showed a numerical but non-significant difference in heart failure events. The researchers call for prospective validation with protocol-standardized blood sampling and blinded outcome adjudication before any clinical use. Still, the core achievement stands: a leakage-controlled, multi-cohort-validated blood-based gene index that captures the immune fingerprint of heart attack, built entirely on transparent, reproducible analysis of public data. If prospective studies confirm its accuracy, such a signature could one day complement troponin testing and help identify which patients carry the inflammatory profiles most likely to benefit from emerging immune-targeted therapies, from IL-6 receptor blockade to NLRP3 inhibitors now advancing through clinical development.

Subject of Research: A machine learning-derived eight-gene blood transcriptomic index for diagnosing acute myocardial infarction and characterizing its inflammatory immune response

Article Title: Cross-cohort blood transcriptome analysis identifies an eight-gene diagnostic index and inflammatory programs in acute myocardial infarction

Article References: Pan, C., Chen, Z., Li, J., Xie, S., & Fan, X. (2026). Cross-cohort blood transcriptome analysis identifies an eight-gene diagnostic index and inflammatory programs in acute myocardial infarction. Frontiers in Cardiovascular Medicine, 13, Article 1904246. https://doi.org/10.3389/fcvm.2026.1904246

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1904246

Keywords: acute myocardial infarction, blood transcriptomics, machine learning, diagnostic gene signature, inflammasome, NLRP3, immune response, WGCNA, biomarker validation, precision cardiology, CXCL10, heart failure